Fast MDX - Model NGX 124 - Automated Molecular Diagnostics (MDX) Test Platform
The NGX 124 is a fully open, automated molecular diagnostics (MDx) test platform, offering a significant advantage over other systems. It supports all Laboratory Developed Tests (LDTs), Research Use Only (RUO), and approved assays sourced directly from a wide range of small and medium sized assay manufacturers.
- Increased competition in the assay and reagent market, driving down costs.
- Economies of scale in reagent and assay production, further reducing expenses.
- Enhanced laboratory efficiency through streamlined automated testing.
- Elimination of manual handling errors via precise robotic liquid handling.
- User-friendly, intuitive interface, enabling a single technician to manage high-throughput testing, freeing up biomedical scientists for more complex tasks.
- Zero capital expenditure: the NGX 124 platform is provided free of charge, with a simple pay-per-test model.
- Flexible 3-month rolling contract with no long-term commitments.
- No maintenance, servicing, or warranty costs.
- Compact design, occupying just 0.7m2 of floor space, making it the smallest high-throughput platform.
- Up to 1,564 samples can be automatically tested in an 8 hour shift.
Jointly designed and developed by Fast MDx and Festo, the Fast MDx platform is the first fully automated, high-throughput, mobile Molecular Diagnostic (MDx) test platform and incorporates Fast MDx’s latest, ultra-fast, “NGx2” 4-Channel qPCR thermal cycler and Reverse Transcription “RT” block technology…
Compact, mobile and rugged on 4 lockable casters, Fast MDx can be used anywhere in the World. Small enough to fit through any doorway and into any elevator, Fast MDx is as much at home in a biosecure laboratory as it is in a hospital facility…
Fast MDx aims to provide affordable MDx to all peoples of the world, regardless of income or location…